Wednesday, July 8, 2026

Patent intelligence · US

US 12097230

Method and composition for treating post operative conditions

granted A61KA61K31/05A61K31/352A61K36/185
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 57
Patent details — US 12097230
Jurisdiction
US
Status
granted
Grant date
Sep 24, 2024
Expiration
Sep 19, 2044
Claims
1
CPC classes
A61K, A61K31/05, A61K31/352, A61K36/185
View on Google Patents ↗

Quick answer

US 12097230 (Method and composition for treating post operative conditions) is held by Bright Green Corporation. Status: granted. Granted Sep 24, 2024. Expires Sep 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
1
CPC classes
A61K, A61K31/05, A61K31/352, A61K36/185, A61K9/0095

More from Bright Green Corporation

Related pharmaceutical patents in our USPTO index.

  1. US 12383631

    Immune antigen specific IL-18 immunocytokines and uses thereof

    Bright Peak Therapeutics AG · Expires Aug 7, 2045

    granted
  2. US 12350120

    Gum-protecting and teeth-whitening strip and preparation method thereof

    Jiangxi Dentalbright Technology Co., Ltd. · Expires Jul 3, 2045

    granted
  3. US 12220447

    Proteolytic enzyme composition

    Bright Lifecare PVT LTD. · Expires Feb 6, 2045

    granted
  4. US 12215133

    GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use

    BrightGene Bio-Medical Technology Co., Ltd. · Expires Jan 30, 2045

    granted
  5. US 12173062

    Modified TNF-α antibodies and uses thereof

    Bright Peak Therapeutics AG · Expires Dec 19, 2044

    granted
  6. US 12115136

    Fortified CBD oil for treatment of PTSD

    Bright Green Corporation · Expires Oct 10, 2044

    granted
  7. US 11925686

    Materials for phototherapies of ophthalmic diseases

    EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD. · Expires Mar 7, 2044

    granted

Frequently asked questions

What is US patent 12097230?

US 12097230 (Method and composition for treating post operative conditions) is held by Bright Green Corporation. Status: granted. Granted Sep 24, 2024. Expires Sep 19, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12097230?

Bright Green Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.

When does US 12097230 expire?

Our index shows an expiration date of Sep 19, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.